Neurological Infectious Diseases in the ICU: Contemporary Management Strategies

Dr Neeraj Manikath , claude.ai

Abstract

Neurological infections represent some of the most challenging presentations in critical care, demanding rapid diagnosis and aggressive management to prevent irreversible neurological injury. This review addresses three critical domains: refractory meningitis and encephalitis, autoimmune encephalitis, and central nervous system infections in immunocompromised hosts. We provide evidence-based management strategies, diagnostic pearls, and practical approaches for the intensivist managing these complex patients.

Introduction

Central nervous system (CNS) infections carry mortality rates ranging from 10-30% despite modern antimicrobial therapy, with survivors often experiencing significant neurological sequelae. The intensivist must navigate diagnostic uncertainty, institute empiric therapy rapidly, and recognize atypical presentations that may herald uncommon pathogens or immune-mediated processes. This review synthesizes current evidence and provides actionable guidance for managing these critical neurological emergencies.

Managing Refractory Meningitis and Encephalitis

Defining Refractory Disease

Refractory meningitis or encephalitis is characterized by clinical deterioration or failure to improve after 48-72 hours of appropriate antimicrobial therapy. This scenario demands systematic reassessment of the initial diagnostic and therapeutic approach.

Pearl #1: The mnemonic "WRONG BUG, WRONG DRUG, WRONG PENETRATION" helps structure evaluation of treatment failure.

Diagnostic Reassessment

When patients fail to respond, consider:

Wrong Bug Scenarios:

1. Tuberculous meningitis (TBM): Often misdiagnosed initially as bacterial meningitis. CSF typically shows lymphocytic pleocytosis (10-500 cells/μL), elevated protein (1-5 g/L), and low glucose (<50% of serum). The adenosine deaminase (ADA) level >10 U/L has 93% sensitivity for TBM in HIV-negative patients. CSF Xpert MTB/RIF has revolutionized diagnosis with 80% sensitivity when 6mL CSF is used.

2. Fungal meningitis: Cryptococcal meningitis presents with minimal CSF pleocytosis. India ink stain is only 50% sensitive; cryptococcal antigen has 95% sensitivity. Histoplasma, Coccidioides, and Blastomyces require specific serological and culture techniques.

3. Viral encephalitis beyond HSV: Enterovirus, West Nile virus, Japanese encephalitis, and emerging arboviruses require specific PCR testing. Hack: Order a comprehensive viral encephalitis panel early—results take days, and empiric acyclovir doesn't cover these pathogens.

Pearl #2: Repeat lumbar puncture at 48-72 hours is crucial. Failure of CSF parameters to improve (particularly persistent neutrophilia, unchanged glucose, or rising protein) suggests wrong diagnosis or inadequate therapy.

Wrong Drug Considerations

Antimicrobial Resistance:

• Penicillin-resistant Streptococcus pneumoniae (MIC >2 μg/mL) requires ceftriaxone 2g Q12h PLUS vancomycin targeting trough 15-20 μg/mL
• Carbapenem-resistant Gram-negatives may require intrathecal or intraventricular antimicrobials
• Oyster: Adding rifampin to vancomycin for pneumococcal meningitis is controversial—some studies show antagonism

CNS Penetration Issues

CSF antimicrobial levels are critical. Drugs with poor BBB penetration include:

• First-generation cephalosporins
• Aminoglycosides (requiring intrathecal administration)
• Amphotericin B deoxycholate (<5% CNS penetration; liposomal formulation preferred at 6-10 mg/kg/day)

Hack: Dexamethasone, while beneficial for pneumococcal meningitis mortality, reduces vancomycin CNS penetration by 30-50%. Consider withholding steroids if vancomycin-resistant organisms are suspected until cultures clarify.

Adjunctive Therapies in Refractory Cases

Corticosteroids: The ESCMID guidelines recommend dexamethasone 10mg Q6h for bacterial meningitis, started before or with the first antibiotic dose. However, for TBM, higher doses (12-16mg daily) and longer duration (6-8 weeks taper) reduce mortality in HIV-negative patients (RR 0.75, 95% CI 0.65-0.87).

Intrathecal/Intraventricular Therapy: Reserved for:

• Extensively drug-resistant organisms
• Ventriculitis with inadequate systemic penetration
• Dosing: Vancomycin 5-20mg daily, gentamicin 5-10mg daily, colistin 125,000 IU daily

Hyperbaric Oxygen: Anecdotal success in gas gangrene-associated meningitis and severe pneumococcal cases, but no RCT evidence.

Complications Demanding ICU Intervention

Increased Intracranial Pressure (ICP):

• Maintain CPP >60 mmHg
• Osmotherapy: Hypertonic saline (3% bolus 250mL) preferred over mannitol in bacterial meningitis
• Pearl #3: Serial therapeutic LPs (removing 20-30mL CSF) can be life-saving in cryptococcal meningitis with elevated opening pressure >25 cm H₂O

Seizures: Occur in 15-25% of encephalitis cases. Levetiracetam 1000-1500mg Q12h is preferred (no hepatic metabolism, minimal drug interactions).

Cerebral Venous Sinus Thrombosis (CVST): Complicates 5-10% of bacterial meningitis cases. MR venography should be performed if neurological deterioration occurs despite appropriate antibiotics. Anticoagulation is recommended despite theoretical bleeding risk.

Autoimmune Encephalitis: Diagnosis and ICU Management

Recognition and Diagnosis

Autoimmune encephalitis (AE) represents a paradigm shift in our understanding of "viral" encephalitis. Up to 20% of patients with suspected viral encephalitis actually have antibody-mediated disease.

Clinical Red Flags for AE:

1. Subacute cognitive decline (<3 months)
2. Psychiatric symptoms preceding neurological findings
3. Movement disorders (orofacial dyskinesias, dystonia)
4. Autonomic instability
5. Refractory seizures or status epilepticus
6. Hyponatremia (SIADH)
7. MRI showing medial temporal lobe T2/FLAIR hyperintensity

Pearl #4: The triad of psychiatric symptoms + hyponatremia + abnormal movements should immediately trigger AE workup, particularly anti-NMDA receptor encephalitis.

Diagnostic Workup

CSF Analysis:

• Lymphocytic pleocytosis (20-100 cells/μL) in 80% of cases
• Mildly elevated protein (<1 g/L)
• Oyster: Normal CSF doesn't exclude AE—10-20% have acellular CSF

Antibody Testing:

• Send both serum and CSF for antibody panels
• Hack: CSF is more sensitive than serum for NMDA-R, GABA-B-R, and AMPA-R antibodies; serum is more sensitive for LGI1 and CASPR2
• Antibodies may take 2-3 weeks to result—don't delay treatment

Common Antibodies and Clinical Syndromes:

• Anti-NMDA-R: Young women, ovarian teratoma (60% in women >18yo), psychiatric prodrome, dyskinesias, autonomic instability, hypoventilation
• Anti-LGI1: Older men, faciobrachial dystonic seizures, hyponatremia
• Anti-GABA-B-R: High seizure burden, associated with small cell lung cancer (50%)
• Anti-MOG: Pediatric cases, optic neuritis, often post-infectious

EEG Findings:

• Extreme delta brush (1-2 Hz delta with superimposed beta) is pathognomonic for anti-NMDA-R encephalitis
• Continuous slow activity common in all forms

Imaging:

• MRI abnormal in only 50% of AE cases
• FLAIR hyperintensity in medial temporal lobes, hippocampi
• FDG-PET may show characteristic patterns when MRI is normal

ICU Management

First-Line Immunotherapy: The treatment algorithm follows established protocols:

1. Corticosteroids: Methylprednisolone 1g IV daily × 5 days
2. IVIG: 0.4 g/kg/day × 5 days (total 2 g/kg)
3. Plasma Exchange (PLEX): 5-7 exchanges over 10-14 days

Pearl #5: Start immunotherapy empirically if clinical suspicion is high, even before antibody confirmation. Delays >4 weeks from symptom onset worsen outcomes.

Combination vs. Sequential Therapy: A recent retrospective analysis suggested combining PLEX + methylprednisolone + IVIG upfront may be superior to sequential therapy in severe cases (mRS 4-5), though RCT data are lacking.

Second-Line Immunotherapy: If no improvement after 10-14 days of first-line therapy:

• Rituximab: 375 mg/m² weekly × 4 weeks, or 1000mg on days 1 and 15
• Cyclophosphamide: 750 mg/m² monthly × 6 months

Hack: Consider early escalation to second-line therapy (by day 7) in anti-NMDA-R encephalitis requiring ICU admission, as these patients have worse outcomes with delayed escalation.

Critical Care-Specific Management

Autonomic Instability:

• Blood pressure lability managed with short-acting agents (clevidipine, esmolol)
• Cardiac arrhythmias common; telemetry essential
• Temperature dysregulation may mimic neuroleptic malignant syndrome

Hypoventilation:

• Central hypoventilation common in anti-NMDA-R encephalitis
• May require prolonged mechanical ventilation (median 4-6 weeks)
• Pearl #6: Avoid sedation-vacation protocols; patients often require continuous sedation due to agitation and dyskinesias
• Tracheostomy often necessary; consider early (7-10 days)

Movement Disorders:

• Orofacial dyskinesias, choreoathetosis, dystonia
• Benzodiazepines first-line
• Consider tetrabenazine or deutetrabenazine for severe choreoathetosis
• Oyster: Avoid typical antipsychotics—they worsen symptoms and carry NMS risk

Seizure Management:

• Treat seizures aggressively; status epilepticus occurs in 30%
• Standard AEDs often ineffective
• Consider ketamine infusion for refractory status (synergistic with immunotherapy in anti-NMDA-R encephalitis)

Tumor Screening:

• MRI chest/abdomen/pelvis
• Transvaginal ultrasound or CT pelvis for ovarian teratoma (anti-NMDA-R)
• CT chest for small cell lung cancer (anti-GABA-B-R, anti-AMPA-R)
• Hack: Repeat imaging at 6 months and 12 months if initially negative—tumors may be occult

Prognosis

Overall, 70-80% of AE patients achieve good functional recovery (mRS 0-2) by 24 months, though recovery is prolonged. Poor prognostic factors include ICU admission, delayed treatment >4 weeks, need for second-line immunotherapy, and older age.

CNS Infections in the Immunocompromised Host

Risk Stratification

Immunocompromised hosts encompass diverse populations with varying CNS infection risks:

Neutropenia (<500 cells/μL):

• Bacterial: Pseudomonas, enteric Gram-negatives, Listeria
• Fungal: Aspergillus (most common), Mucor, Candida
• Duration >7 days exponentially increases risk

T-Cell Deficiency (HIV, transplant, chemotherapy):

• Viral: CMV, VZV, JC virus (PML), HSV-6
• Fungal: Cryptococcus, Histoplasma
• Parasitic: Toxoplasma gondii
• Bacterial: Listeria, Nocardia, tuberculosis

Complement Deficiency/Asplenia:

• Encapsulated organisms: S. pneumoniae, N. meningitidis, H. influenzae

Pearl #7: The CD4 count in HIV patients predicts specific opportunistic infections: <200 for cryptococcus, <100 for toxoplasmosis, <50 for CMV and MAC.

Clinical Presentation and Diagnosis

Atypical Presentations: Immunocompromised patients often lack typical inflammatory responses:

• Minimal fever or leukocytosis
• Paucicellular CSF (WBC <50 even with severe infection)
• Subtle or absent meningismus
• Subacute progression over days to weeks

Imaging Characteristics:

• Toxoplasmosis: Multiple ring-enhancing lesions with predilection for basal ganglia; "eccentric target sign"
• Primary CNS Lymphoma: Periventricular enhancement, crosses corpus callosum
• PML: Asymmetric subcortical white matter T2 hyperintensity without enhancement or mass effect
• Aspergillosis: Hemorrhagic infarction from angioinvasion; "hypodense sign" on CT

Hack: The Thallium-201 SPECT scan can differentiate toxoplasmosis (cold lesions) from lymphoma (hot lesions) when biopsy is high-risk, though PET-CT is increasingly used.

Empiric Therapy Approach

Given diagnostic uncertainty and high mortality, broad empiric coverage is essential:

Bacterial Coverage:

• Ampicillin 2g Q4h (for Listeria)
• Vancomycin 15-20 mg/kg Q8-12h
• Ceftazidime 2g Q8h or meropenem 2g Q8h (antipseudomonal)

Fungal Coverage:

• Liposomal amphotericin B 5-7.5 mg/kg/day
• Consider voriconazole 6 mg/kg Q12h × 2 doses, then 4 mg/kg Q12h for mold coverage

Viral Coverage:

• Acyclovir 10 mg/kg Q8h (adjust for renal function)
• Consider ganciclovir 5 mg/kg Q12h if CMV suspected

Parasitic (HIV/transplant):

• Pyrimethamine 200mg loading, then 50-75mg daily + sulfadiazine 1-1.5g Q6h + leucovorin 10-20mg daily for empiric toxoplasmosis

Pearl #8: In HIV patients with CD4 <50 and ring-enhancing lesions, treat empirically for toxoplasmosis for 10-14 days before pursuing brain biopsy. Clinical and radiographic improvement should be evident by 2 weeks.

Specific Pathogens and Management

Cryptococcal Meningitis:

• Induction: Liposomal amphotericin B 3-4 mg/kg/day (some recommend 6 mg/kg in HIV) + flucytosine 100 mg/kg/day divided Q6h × 2 weeks
• Critical: Serial therapeutic LPs to maintain opening pressure <20 cm H₂O; this is more important than antimicrobials for survival
• Consolidation: Fluconazole 400mg daily × 8 weeks
• Maintenance: Fluconazole 200mg daily ×≥1 year
• Oyster: Steroids are contraindicated in cryptococcal meningitis—they increase mortality

Toxoplasma Encephalitis:

• Treatment as above; alternatives for sulfa allergy: clindamycin 600mg Q6h + pyrimethamine/leucovorin
• Continue therapy until CD4 >200 for ≥6 months on ART

Progressive Multifocal Leukoencephalopathy (PML):

• No specific therapy; restore immune function
• HIV patients: Start ART immediately (despite IRIS risk)
• Transplant patients: Reduce immunosuppression if possible
• Experimental: Some centers use checkpoint inhibitors (pembrolizumab) or 5-HT2a antagonists (mirtazapine), but evidence is anecdotal

Invasive Aspergillosis:

• Voriconazole 6 mg/kg Q12h × 2, then 4 mg/kg Q12h (target trough 2-5 μg/mL)
• Liposomal amphotericin B 5-7.5 mg/kg/day if voriconazole-resistant or intolerant
• Combination therapy (voriconazole + anidulafungin) for severe cases
• Surgical resection for single lesions causing mass effect
• Pearl #9: Monitor voriconazole levels—genetic polymorphisms cause 10-fold variability in metabolism

Cytomegalovirus (CMV) Encephalitis/Ventriculitis:

• Ganciclovir 5 mg/kg Q12h + foscarnet 60 mg/kg Q8h (combination superior to monotherapy)
• Treatment duration ≥3 weeks, often longer
• CSF CMV PCR should become undetectable; repeat LP to confirm

Immune Reconstitution Inflammatory Syndrome (IRIS)

IRIS occurs in 10-25% of HIV patients starting ART with underlying CNS infections. It represents a double-edged sword—immune restoration with pathological inflammation.

Risk Factors:

• CD4 <50 cells/μL at ART initiation
• High baseline pathogen burden
• Rapid CD4 recovery
• Starting ART within 2-4 weeks of CNS infection diagnosis

Clinical Presentation:

• Paradoxical worsening after initial improvement
• Occurs 2-8 weeks after starting ART
• New neurological deficits, seizures, increased ICP

Management:

• Continue ART (do not stop)
• Corticosteroids: Prednisone 1-2 mg/kg/day for 2-4 weeks, then taper
• Ensure adequate antimicrobial therapy for underlying infection
• Serial imaging to monitor for new lesions or progression

Hack: The decision to start ART in a critically ill patient with CNS opportunistic infection is controversial. For cryptococcal meningitis, guidelines recommend delaying ART 4-6 weeks. For toxoplasmosis or PML, earlier initiation may be beneficial despite IRIS risk. Individualize based on CD4 count and overall clinical status.

Non-Infectious Mimics

Always consider non-infectious etiologies in immunocompromised patients:

• Primary CNS lymphoma: Ring-enhancing lesions, periventricular, crosses corpus callosum
• Drug toxicity: Methotrexate, cyclosporine, tacrolimus (PRES)
• Metabolic: Progressive multifocal leukoencephalopathy-like changes from chemotherapy
• Stroke: Thrombotic microangiopathy from immunosuppressants

Prophylaxis Considerations

Post-recovery prophylaxis prevents recurrence:

• Cryptococcus: Fluconazole 200mg daily until CD4 >200 ×6 months
• Toxoplasma: TMP-SMX DS daily until CD4 >200 ×3 months
• CMV: Valganciclovir 900mg daily in high-risk transplant patients

Conclusion

Neurological infections in the ICU demand a systematic, evidence-based approach tempered with clinical judgment. Early empiric therapy, aggressive diagnostic evaluation, recognition of atypical presentations, and consideration of immune-mediated phenomena are critical. The intensivist must balance the urgency of treatment with the precision required for accurate diagnosis, often navigating diagnostic uncertainty in critically ill patients where delays prove fatal. As our understanding of autoimmune encephalitis expands and emerging pathogens threaten immunocompromised populations, remaining vigilant and adaptable in management strategies will optimize outcomes in these challenging cases.

---

Key References

1. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-62.

2. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303-27.

3. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.

4. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322.

5. Thakur KT, Wilson MR, Lucchesi C, et al. Metagenomic Next-Generation Sequencing for Diagnosis of CNS Infections. Clin Infect Dis. 2021;73(9):e3176-e3185.

6. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-65.

7. Mai NTH, Dobbs N, Phu NH, et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. eLife. 2018;7:e33478.

8. Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.

9. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-98.

10. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;2015(9):CD004405.